Good Manufacturing Practices (GMP) – Page 5

Inadequate GMP training during routine manufacturing – evidence package for inspection defense

Identifying inadequate GMP training begins with recognizing symptoms or signals on the manufacturing floor or within laboratory environments. Key indicators may include:Click to read the full article.

Weak management oversight during scale-up – root cause analysis inspectors expect

Identifying early symptoms or signals that indicate weak management oversight is vital for mitigative actions. These symptoms can manifest in various forms across the manufacturing and laboratory environments.Click to read…

Weak management oversight during technology transfer – root cause analysis inspectors expect

Identifying symptoms early can prevent compliance issues from escalating into regulatory actions. The following are key signs that indicate potential weak management oversight during technology transfer:Click to read the full…

Poor change control discipline during routine manufacturing – root cause analysis inspectors expect

Recognizing the early signs of poor change control is essential for mitigating risk. Indicators may vary across departments but commonly include:Click to read the full article.

Poor change control discipline during routine manufacturing – FDA/EMA inspection citation risk

Identifying symptoms of poor change control discipline begins at the manufacturing floor or within laboratory settings. Here are key signals that may indicate underlying issues:Click to read the full article.

Uncontrolled SOP changes during scale-up – how to rebuild GMP maturity

Identifying early symptoms is crucial for preventing broader issues that can arise from uncontrolled SOP changes. Key signals include:Click to read the full article.

Inconsistent GMP interpretation during regulatory inspection – FDA/EMA inspection citation risk

Recognizing red flags at the first signs of GMP interpretation inconsistencies is crucial. Symptoms may vary across different roles, but common indicators include:Click to read the full article.

Inadequate GMP training during scale-up – CAPA framework to prevent recurrence

Recognizing the signs of inadequate GMP training is crucial. Symptoms may include:Click to read the full article.

Uncontrolled SOP changes during scale-up – FDA/EMA inspection citation risk

Understanding the early signs of uncontrolled SOP changes is crucial. Look for the following signals:Click to read the full article.

Repeated GMP deviations during internal audit – evidence package for inspection defense

Identifying symptoms of repeated GMP deviations is crucial in ensuring that issues are addressed promptly. Common signals include:Click to read the full article.